What it is (overview)

A prostate biopsy with imaging guidance is a diagnostic procedure in urology where a clinician removes small tissue samples from the prostate gland to be examined under a microscope. “Imaging guidance” means the biopsy needles are guided using real-time imaging—most commonly transrectal ultrasound (TRUS), MRI, or an MRI-ultrasound fusion system. Imaging helps target suspicious areas more accurately than a non-targeted (systematic) biopsy alone.

The test does not measure a number like a blood test. Instead, it provides a pathology report based on what the cells look like. Results typically include:

• No cancer found: Samples show benign (non-cancerous) prostate tissue. This can be reassuring, but it does not always fully rule out prostate cancer—especially if PSA levels remain high or imaging remains suspicious. Your clinician may recommend continued PSA monitoring, repeat MRI, or (sometimes) a repeat biopsy depending on your risk.

• Prostate cancer found: The report usually includes a Gleason score / Grade Group (how aggressive the cancer cells appear), whether cancer is present in one or more cores, and how much of each core is involved. These details help guide next steps, such as active surveillance, surgery, or radiation therapy.

• Precancerous or atypical changes: Findings like high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) may indicate higher risk and often lead to closer follow-up or repeat targeted sampling.

• Inflammation or infection: Prostatitis or inflammatory changes may help explain symptoms and/or elevated PSA levels. Treatment and follow-up plans may be adjusted based on these findings.

Biopsies are commonly performed through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). Your urology team will choose the approach and imaging method based on your anatomy, MRI findings, infection risk, and local expertise.

When & why it's usually done

A prostate biopsy with imaging guidance is usually done when there is a concern for an abnormal prostate and your clinician needs tissue confirmation to diagnose or rule out prostate cancer. It is often recommended after screening tests or imaging suggest increased risk.

Common reasons your doctor may order an imaging-guided prostate biopsy include:

• Elevated or rising PSA levels: PSA is a blood marker that can increase due to cancer, enlarged prostate (BPH), inflammation, or recent urinary procedures. A persistently high PSA or a concerning PSA trend (such as a rapid rise) may prompt biopsy consideration.

• Abnormal digital rectal exam (DRE): If the clinician feels a lump, firmness, asymmetry, or other irregularity on the prostate, a biopsy may be recommended to determine the cause.

• Suspicious findings on prostate MRI: Multiparametric MRI can identify areas that look concerning for clinically significant cancer. Imaging guidance allows targeted biopsy of these regions, improving detection compared with random sampling alone.

• Prior negative biopsy but ongoing concern: If you previously had a prostate biopsy with negative results but PSA levels keep rising or MRI shows a new or persistent lesion, imaging-guided repeat biopsy may be advised.

• Higher-risk personal factors (men’s health and risk assessment): This includes a strong family history of prostate cancer, known hereditary cancer syndromes (e.g., BRCA-related risk), African ancestry (associated with higher risk in many populations), or older age. Your urology clinician may also consider prostate size, PSA density, and other risk calculators.

The goal of an imaging-guided diagnostic procedure is to get the most accurate information with the fewest samples needed. Accurate biopsy results help avoid both missed cancers and unnecessary treatment of low-risk disease.

Common diseases related to it

• Prostate cancer (including clinically significant prostate cancer)
• Benign prostatic hyperplasia (BPH) / enlarged prostate
• Prostatitis (inflammation or infection of the prostate)
• High-grade prostatic intraepithelial neoplasia (HGPIN)
• Atypical small acinar proliferation (ASAP) / atypical glands
• Prostatic intraepithelial neoplasia and other premalignant or suspicious cellular changes

Health goals where it may help

• Confirming or ruling out prostate cancer after abnormal PSA levels, DRE, or MRI findings
• Clarifying the cause of an abnormal prostate evaluation to guide the next steps in urology care
• Risk stratification and treatment planning (e.g., deciding between active surveillance vs. treatment)
• Monitoring men’s health when PSA trends are concerning or when imaging shows a suspicious lesion
• Improving diagnostic accuracy by using imaging guidance to target areas most likely to contain significant disease
• Supporting peace of mind and informed decision-making by providing tissue-based answers